BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24747001)

  • 1. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
    Tsao AS; Harun N; Fujimoto J; Devito V; Lee JJ; Kuhn E; Mehran R; Rice D; Moran C; Hong WK; Shen L; Suraokar M; Wistuba I
    Ann Diagn Pathol; 2014 Jun; 18(3):140-5. PubMed ID: 24747001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.
    Tsao AS; Wei W; Kuhn E; Spencer L; Solis LM; Suraokar M; Lee JJ; Hong WK; Wistuba II
    Clin Lung Cancer; 2011 Nov; 12(6):369-74. PubMed ID: 21729646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
    Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
    J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
    Tsao AS; Lin H; Carter BW; Lee JJ; Rice D; Vaporcyan A; Swisher S; Mehran R; Heymach J; Nilsson M; Fan Y; Nunez M; Diao L; Wang J; Fujimoto J; Wistuba II; Hong WK
    J Thorac Oncol; 2018 Feb; 13(2):246-257. PubMed ID: 29313814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
    [No Abstract]   [Full Text] [Related]  

  • 9. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
    Ahmadzada T; Lee K; Clarke C; Cooper WA; Linton A; McCaughan B; Asher R; Clarke S; Reid G; Kao S
    Lung Cancer; 2019 Apr; 130():35-41. PubMed ID: 30885349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
    Rena O; Boldorini LR; Gaudino E; Casadio C
    J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
    Gordon GJ; Dong L; Yeap BY; Richards WG; Glickman JN; Edenfield H; Mani M; Colquitt R; Maulik G; Van Oss B; Sugarbaker DJ; Bueno R
    J Natl Cancer Inst; 2009 May; 101(9):678-86. PubMed ID: 19401544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.
    Cedrés S; Montero MA; Zamora E; Martínez A; Martínez P; Fariñas L; Navarro A; Torrejon D; Gabaldon A; Ramon Y Cajal S; Felip E
    Clin Transl Oncol; 2014 Sep; 16(9):776-82. PubMed ID: 24323466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
    Riquelme E; Suraokar MB; Rodriguez J; Mino B; Lin HY; Rice DC; Tsao A; Wistuba II
    J Thorac Oncol; 2014 Jul; 9(7):998-1007. PubMed ID: 24926545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
    Ghanim B; Hoda MA; Winter MP; Klikovits T; Alimohammadi A; Hegedus B; Dome B; Grusch M; Arns M; Schenk P; Pohl W; Zielinski C; Filipits M; Klepetko W; Berger W
    Ann Surg; 2012 Aug; 256(2):357-62. PubMed ID: 22750759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.